Opportunity Radar

← Back to search

Grant

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
CA
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
PAR-28-042
Posted
Nov 3, 2026
Response due
Nov 16, 2029
Archive date
Jan 15, 2030
CFDA / Assistance listing
93.CA1
Contact
NCICDPNOFO@mail.nih.gov
Source
Grants.gov

Description

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.

Similar open opportunities